Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Common Equity: 2019-2025

Historic Common Equity for Benitec Biopharma (BNTC) over the last 6 years, with Mar 2025 value amounting to $317.7 million.

  • Benitec Biopharma's Common Equity rose 2662.22% to $317.7 million in Q1 2025 from the same period last year, while for Mar 2025 it was $317.7 million, marking a year-over-year increase of 2662.22%. This contributed to the annual value of $47.2 million for FY2024, which is 23290.10% up from last year.
  • Per Benitec Biopharma's latest filing, its Common Equity stood at $317.7 million for Q1 2025, which was up 12.84% from $281.5 million recorded in Q4 2024.
  • Benitec Biopharma's Common Equity's 5-year high stood at $317.7 million during Q1 2025, with a 5-year trough of $202,000 in Q2 2023.
  • Over the past 3 years, Benitec Biopharma's median Common Equity value was $22.3 million (recorded in 2023), while the average stood at $85.0 million.
  • In the last 5 years, Benitec Biopharma's Common Equity slumped by 92.99% in 2023 and then skyrocketed by 23,290.10% in 2024.
  • Benitec Biopharma's Common Equity (Quarterly) stood at $10.8 million in 2021, then fell by 17.00% to $9.0 million in 2022, then soared by 72.00% to $15.5 million in 2023, then soared by 1,719.64% to $281.5 million in 2024, then skyrocketed by 2,662.22% to $317.7 million in 2025.
  • Its Common Equity stands at $317.7 million for Q1 2025, versus $281.5 million for Q4 2024 and $64.2 million for Q3 2024.